The Boao Lecheng International Medical Tourism Pilot Zone in Hainan province has released pricing for China's first batch of ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

Autologous mononuclear cells showed substantial activity in patients with advanced heart failure — and even though the study ...

Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) ...

The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty ...

The following is a summary of "A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study," ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

With 26.6% of the European market share in 2022, the U.K. is recognized as a lucrative market for cell therapy manufacturing. Support from regulatory bodies like the European Medicines Agency (EMA) ...

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.